about
Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We NeedDefining the pharmacist role in the pandemic outbreak of novel H1N1 influenza.A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin.Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs PatientsRelationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosaPharmacokinetic and pharmacodynamic profile of ceftobiprole.Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin.Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success.Incidence and Clinical Predictors of Nonresponse to Hepatitis B Vaccination among Patients Receiving Hemodialysis: Importance of Obesity.A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients.Universal precautions in Central Asia: the need for multiple strategies in this window of opportunity.Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study.Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV.Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates.Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae.Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series.Vancomycin: we can't get there from here.Reimbursement for clinical servicesShort Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral TherapyPotential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
P50
Q28067411-B006648C-6379-4C73-807B-C9DC20A314CCQ30424641-5F675F4D-766B-4DD1-B13C-A5BFA1F6DA06Q33398776-98794B37-1C1B-4A13-8908-FEA7E0A9A9E4Q33559047-37F6AEAD-786A-4AA8-AF65-14483318E118Q34737743-84FC3B48-4CD8-4D62-B19F-4CD417C28ED1Q34926950-40D7AC48-6A87-4CCA-AF46-ABA9158E944DQ34991274-5E87BE40-32FD-4017-A126-52C133A325B0Q35191519-DD8A90C1-35ED-41C1-B001-30E8A7D54C7CQ35939695-A99E335C-7C67-474E-91EC-F5F8885F74ACQ35999714-6802E6B0-D5C6-4B64-B23F-7502B6C6F340Q36803995-63023E59-0B36-49DE-81C1-CF00BAC7A37BQ37126977-61475873-D9FD-4D96-96E6-6350088C28FDQ37335621-33335BB8-2150-4C4A-891D-378C3BD85042Q37782190-7FED4656-6DA1-4272-B57E-E7C7909FF47BQ40581914-915FCEDF-F154-4937-9F7E-A83A5811AD08Q41468316-43D1C1B2-8D81-4D1B-BB7C-4A6C598B0013Q41521149-42782094-417B-4D77-8A6D-9834B849E80FQ41644578-BEED0EA1-57F1-4176-8930-1F03D0CF19E9Q41865178-5054C125-EB36-467F-9D9E-F4AEB6FB38E0Q42687513-645E1860-570C-438B-890F-0C11A9B12855Q42926939-8BCE67FD-E66F-412E-90D2-B04D01BD2847Q43620147-09FBB1A8-743C-4AA9-894B-16C8C7C7A2F1Q45223414-40F9E4F2-7F17-4630-9867-09BD8D9D0BC0Q45981027-6508D8B9-0D55-4B5D-BC8D-366FCB83A1D7Q49847063-6D257306-2FA1-441A-94D3-B2D3B9A6C382Q51608468-E35428D0-932C-4BE0-8070-9F9A3CC6AC65Q80236362-24E0DF8C-CBCE-4207-BB3B-2DB316022B52Q90906774-7FF38808-7ABF-4D2A-8B11-0E7990A7E9E8Q90933539-33CD90FC-8022-46A8-9F82-F3BA95442925
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nimish Patel
@ast
Nimish Patel
@en
Nimish Patel
@es
Nimish Patel
@nl
Nimish Patel
@sl
type
label
Nimish Patel
@ast
Nimish Patel
@en
Nimish Patel
@es
Nimish Patel
@nl
Nimish Patel
@sl
prefLabel
Nimish Patel
@ast
Nimish Patel
@en
Nimish Patel
@es
Nimish Patel
@nl
Nimish Patel
@sl
P108
P106
P1153
16029598400
P21
P2381
P31
P496
0000-0003-0921-549X
P6634
nimish-patel-5977a99